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Cosmesis and Body Image in Patients Undergoing Single-port
Versus Conventional Laparoscopic Cholecystectomy:
A Multicenter Double-blinded Randomized Controlled
Trial (SPOCC-trial)
Georg Lurje, MD,y Dimitri Aristotle Raptis, MD, MSc, PhD, Daniel Christian Steinemann, MD,
Iakovos Amygdalos, MBBS, PhD, Patryk Kambakamba, MD, Henrik Petrowsky, MD, FACS,
Mickae¨l Lesurtel, MD, PhD, Adrian Zehnder, MD,z Roland Wyss, MD,z
Pierre-Alain Clavien, MD, PhD, FACS (Hon), and Stefan Breitenstein, MDz
Objective: To evaluate cosmesis, body image, pain, and quality of life (QoL)
after single-port laparoscopic cholecystectomy (SPLC) versus conventional
4-port laparoscopic cholecystectomy (4PLC).
Background: The impact of SPLC on improving cosmesis, body image, pain,
and QoL has not been evaluated in double-blinded randomized controlled
trials (RCT). This approach therefore remains controversial.
Methods: Between October 2011 and February 2014, 110 patients from 2
centers were randomly assigned to SPLC (n¼ 55) or 4PLC (n¼ 55). Primary
endpoints were a validated cosmesis (3–24 points) and body image (5–20
points) score after 3 and 12 months. Secondary endpoints included operative
duration, postoperative pain, complications, QoL, and length of hospital stay.
Patients, physicians, and nurses were blinded until the seventh postoperative
day.
Results: Demographics were equally distributed between both groups (mean
age: 46 years, SD: 14, 62 females, 34 males). The SPLC-group showed
superior mean cosmesis and body image compared with the 4PLC-group at
12-weeks (21 vs 16, P< 0.001 and 5 vs 6, P¼ 0.013, respectively) and at
1-year (24 vs 16, P< 0.001 and 5 vs 6, P< 0.017, respectively). Operation
duration was longer in the SPLC-group (mean 101 vs 90 minutes, p¼ 0.031).
Although postoperative pain was less in the SPLC-group (mean VAS 1 vs 2,
p¼ 0.005), there were no differences in complications, and length of
hospital-stay.
Conclusions: This is the first multicenter double-blinded RCT reporting
superior short- and long-term cosmetic and body image, postoperative pain,
and QoL in SPLC compared with 4PLC. Although cost-effectiveness is still a
subject of ongoing debate, SPLC should be offered to patients undergoing
surgery for benign gallbladder disease.
Keywords: body image, complications, cosmesis, double-blinded, quality of
life, randomized controlled trial, single port cholecystectomy
(Ann Surg 2015;262:728–735)
G allstone disease constitutes a significant health burden in thewestern world and its incidence has increased more than 20%
over the last 3 decades, affecting 15% of the adult population.1–3
Even though most patients with gallstones are asymptomatic, 20%
will develop biliary colic pain or gallstone complications, such as
acute cholecystitis, cholangitis, or pancreatitis.4 Since Erich Mu¨he’s
historic introduction in 1985,5,6 laparoscopic cholecystectomy (LC)
has emerged as the treatment of choice for benign gallbladder disease
and has widely replaced conventional open cholecystectomy.7 In an
attempt to further reduce operative trauma and improve cosmetic
results after conventional 4-port LC (4PLC), there has been a trend
toward minimizing the number of incisions and ports required. As
such, new operative techniques, such as single-port laparoscopic
cholecystectomy (SPLC),8 were introduced, using refined versions of
existing technology, such as instrumentation that allows greater
articulation and rotation, and new retraction systems. Although
SPLC is regarded as a safe and ‘‘painless’’ procedure,9 the cosmetic
benefit for the patient remains the main attraction of SPLC.
As highlighted in a recent meta-analysis by the Cochrane
Hepato-Biliary Group most of the reported trials today have a flawed
trial design and therefore are likely to draw the wrong conclusions.
As such, the authors concluded that up to now the overall quality of
evidence to support SPLC is low.9 We therefore designed a multi-
center double-blinded randomized controlled (RCT) trial to compare
short- and long-term cosmesis and body image, postoperative pain,
and quality of life (QoL) in patients undergoing elective SPLC versus
4PLC cholecystectomy for benign gallbladder disease.
METHODS
Trial Design
This multicenter double-blinded randomized clinical trial was
conducted to evaluate single-port cholecystectomy (SPLC) versus
conventional 4-port cholecystectomy (4PLC) in patients presenting
with symptomatic gallbladder disease, operated between October
2011 and February 2014. Superiority of SPLC to 4PLC with regards
to cosmesis and body image was hypothesized. The study was
conducted according to the principles of the Declaration of Helsinki
and reported on the basis of the CONSORT statement.10 The protocol
of the trial was approved by the local ethics commission, registered at
clinicaltrials.gov (NCT01278472) and published11 before enrollment
of the first participant.
Sample Size Calculation
A clinically relevant improvement of cosmesis and body
image12 was defined as an improvement of 20% (8 points). Given
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the reported standard deviation (SD) between 4 and 613 with an alpha
of 0.05 and power of 0.90, 2 groups of 49 patients were needed.
Taking an estimated 10% dropout rate into consideration, a total of
110 patients were required.14
Participants
Eligible participants were German-speaking adults admitted
for elective cholecystectomy. Patients with pregnancies, liver cir-
rhosis, coagulopathy (platelet count below 50,000/mL), double
medication on platelet antagonists (acetylsalicylic acid and clopi-
dogrel), or international normalized ratio (INR) above 1.4 were
excluded (Fig. 1, CONSORT Flowsheet). Two Swiss centers parti-
cipated to this trial, the University Hospital Zurich and the Cantonal
Hospital Winterthur.
Study Endpoints
The primary endpoint of the trial was the validated cosmesis
and body image score at 12 weeks and 1 year. This score was
validated in patients undergoing surgery for inflammatory bowel
disease12 and donor nephrectomy.15 Briefly, the body image score
measures the patient’s perception of their body and their attitude
toward their appearance. This score varies between 5 and 20 points,
with a low score meaning a better body image. The assessment of
cosmesis was defined as the degree of patient satisfaction with
respect to the appearance of their scar(s). A scoring system was
used between 3 and 24 points, with a high score meaning a better
cosmetic result.12
Secondary endpoints included operation duration, postopera-
tive pain (visual analogue scale—VAS), complications (Clavien-
Dindo score16,17 and the comprehensive complication index—
CCI18), QoL at 12 weeks and 1 year after surgery (short-form-36
health survey questionnaire SF-3619), and the length of hospital stay.
Data Collection and Statistical Methods
Informed consent and patient enrolment was carried out in the
outpatient clinic. Data included in the patient report forms were
collected on an internet-based secured and encrypted data manage-
ment platform.20 The cosmesis and body image questionnaire, and the
SF-36QoL questionnairewere completed directly by the patient in the
outpatient clinic preoperatively, and 12 weeks and 1 year postoper-
atively. Painvariableswere assessedwith aVASon a daily basis during
hospital stay.11 Patient data were analyzed in the groups to which they
were originally randomly assigned (intention-to-treat analysis). Con-
tinuous variables were compared with the Student t test, the Mann-
WhitneyU test, 1-way ANOVA, and the Kruskal-Wallis H test, where
appropriate. Differences among proportions derived from categorical
data were compared using the Fisher exact test and the Pearson x2 test,
where appropriate. All P values were 2-sided and considered statisti-
cally significant if P< 0.05. Statistical analysis was performed on
SPSS 22 for Mac (IBM Corp, Armonk, NY).
Randomization
A Web-based patient randomization service for multicenter
clinical trials was used (www.randomizer.at).21 The allocation ratio
was 1:1 for both groups. The patients were enrolled to the study by
the responsible surgeon at the time of first outpatient clinic visit, and
the randomization took place on the operative day during the
induction of anesthesia by the responsible surgeon.
Double-blinding
Patients, treating physicians and nurses were blinded until the
seventh postoperative day. The skin was closed intracutaneous with a
running suture. In addition, the wound was sealed using fibrin glue
(DermabonTM; Ethicon Endosurgery Inc, Smithfield, RI) to avoid
any blood spots on the dressing. At the end of the operation four 3M
Tegaderm (5 7 cm, 3M Center, St. Paul, MN) occlusive and water-
resistant wound dressings were applied at the 4 port-sites (as for
4PLC) in both treatment arms. Dressings were marked with a sterile
permanent marker to detect any violation of the blinding. Any
suspicion or confirmation of violation of blinding was recorded.
Surgical Technique
The endoscopic equipment in terms of optic, monitor, gas
supply, suction device, graspers, monopolar hook, and endobag were
equal in both groups. The minimum individual surgeons experience in
LC required to operate on study patients was 10 SPLC and 30 4PLC,
respectively. Study surgeons were required to participate in a 1-day
SPLC workshop. For patients undergoing SPLC a 10mm atraumatic
access devicewas used (SILSTMPT12; Covidien Inc., Norwalk, CT).
Exposure of the gallbladder was achieved through an intra-abdominal
anchored retraction device (EndoGrabTM; Virtual Ports Ltd., Cae-
sarea, Israel) that was introduced and placed at the fundus and the
parietal peritoneum. Exposure of the triangle of Calot and lateral
retraction of the gallbladder infundibulum was performed using a
bending grasper (Endograsp roticulatorTM, Covidien Inc., Norwalk,
CT). A detailed description of the surgical technique for SPLC and
4PLC was described in the publication of the study protocol.11
RESULTS
Patient Flow
Figure 1 illustrates the patient flow according to the CON-
SORT guidelines.10,22,23 Of the 132 patients, assessed for eligibility,
110 were randomized. Seventy percent of the patients were treated at
the University Hospital Zurich, and 30% at the Cantonal Hospital
Winterthur. Fifty-five patients were randomized to single-port chol-
ecystectomy (SPLC) and 55 to conventional 4-port cholecystectomy
(4PLC). Four patients from the SPLC-group and 3 patients from the
4PLC-group were lost in follow-up within the first postoperative
week. In all 7 cases, the patients did not revisit the outpatient clinic
despite reminder letters and direct phone calls to the patients.
Another 3 patients from the SPLC-group and 4 patients from the
4PLC-group were excluded after randomization because of either
patient study consent withdrawal after surgery or incorrect study
inclusion due to faulty inclusion criteria. Finally, 48 patients in each
group were analyzed in this study
Baseline Patient Characteristics
Ninety-six patients [64 women, mean age 46 (SD: 14 years)]
were randomly allocated to SPLC (n¼ 48) and 4PLC (n¼ 48).
Table 1 lists the patients’ characteristics. Age, sex, body mass index,
history of previous abdominal surgery, and other comorbidities were
equally distributed in both groups. There were no statistically
significant differences among the parameters.
Perioperative Characteristics
The mean operation duration was longer in SPLC when
compared to the conventional 4PLC (mean 101 vs 90 minutes,
P¼ 0.031, Table 1). One patient in each group was converted to
open cholecystectomy. Additional trocars were used in 4 patients
with SPLC. There were no significant differences in intraoperative
complication rates, even though, the surgeons ‘‘comfort with the
operation’’ was higher in the 4PLC-group (P¼ 0.002, Table 1).
Cosmesis and Body Image Score After 12 Weeks
and 1 Year
As shown in Table 2 the SPLC-group showed a superior
median cosmesis score when compared with the 4PLC-group after
Annals of Surgery  Volume 262, Number 5, November 2015 Multicenter Randomized Controlled Trial
 2015 Wolters Kluwer Health, Inc. All rights reserved. www.annalsofsurgery.com | 729
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
12 weeks (21 vs 16, P< 0.001) and after 1 year (24 vs 16, P< 0.001,
respectively). Similarly, the body image score was superior at the 12-
week and 1-year follow-up for the SPLC-group when compared with
the 4PLC-group (5 vs 6, P¼ 0.013, 5 vs 6, P¼ 0.017, respectively)
(Table 2).
Postoperative Pain and Analgesic Requirements
Postoperative pain was lower after SPLC compared with
4PLC on postoperative day 2 [1.0 (SD 1.0) vs 2.0 (SD 2.0),
P< 0.001] and day 7 [1.0 (SD 1.0) vs 2.0 (SD 2.0), P< 0.005]
(Table 2). In addition, nonopioid analgesic requirements were sig-
nificantly lower in the SPLC-group when compared with the 4PLC-
group (Table 2).
Postoperative Surgical Complications and Length
of Hospital Stay
With 20% overall complications (Clavien-Dindo, I-V) after
SPLC and 27% after 4PLC, postoperative complication rates were
not different between the groups (P¼ 0.642, Table 3). The mean
Comprehensive Complication Index (CCI) of the highest compli-
cation grade was low and similar [mean 3.2 (7.3) for SPLC and 2.5
(5.1) for 4PLC, P¼ 0.855, CCI: min 0, max 100] between the groups.
Clavien-Dindo IIIa complications occurred in 3 patients after SPLC
(2 ERCPs and 1 chest drain), and in 1 patient after 4PLC (ERCP).
The median hospital stay was similar in both groups (Table 3). There
were 2 umbilical hernias in the SPLC group, compared with no
incisional hernia in patients undergoing 4PLC at 12-month follow-
up. From these 2 SPLC hernias, 1 patient was unknowingly pregnant
during her SPLC-procedure and developed an incisional hernia 4
months after surgery during pregnancy. This difference did not reach
statistical significance (Table 2). In addition, 1 SPLC patient with a
medical history of smoking, chronic obstructive pulmonary disease,
and primary spontaneous pneumothorax developed a spontaneous
pneumothorax postoperatively that required interventional chest-
tube placement.
Quality of Life (SF-36)
Quality of life 12 weeks postoperatively, as assessed by the
SF-36 score, was similar in both groups (Table 4). However, after 1
year, QoL was significantly higher in the SPLC-group compared
with 4PLC-group with regard to emotional wellbeing, physical pain,
physical health, and mental health (Table 4).
Scar Length and Width
At 1-year follow-up, the mean scar length was 21 (SD 24) versus
42mm (SD 22) for the SPLC and 4PLC groups, respectively
FIGURE 1. CONSORT NPT study flow diagram. Adopted from Boutron et al.10
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(P< 0.001). Similarly, the mean scar width was 2 (SD 1) in the SPLC-
group and 3mm (SD 3) in patients undergoing 4PLC (P< 0.001).
DISCUSSION
This is the first double-blinded randomized controlled trial
comparing single port laparoscopic cholecystectomy (SPLC) with 4-
port laparoscopic cholecystectomy (4PLC). Beneficial effects of
SPLC are not only related to an improved postoperative pain profile,
but also to better cosmesis and body image.
In an attempt to further reduce the invasiveness of LC, new
operative techniques, such as SPLC, were introduced.8 Most atten-
tion in assessing its clinical usefulness focused on safety and post-
operative pain. Interestingly, very little has been done to assess the
short- and long-term cosmetic benefit for the patient, although, this
aspect was highly promoted by the industry. Furthermore, it was
highlighted in a recent meta-analysis by the Cochrane Hepato-Biliary
Group that the methodological quality of current studies is too low to
currently support SPLC as the standard of care in patients with
benign gallbladder disease.9 In contrast to previously published
studies, the present trial includes a double-blinded design and a
complete follow-up after 1 year.
This study revealed several important findings. First, superior
short- and long-term cosmesis and body image were the most
significant factors associated with the use of SPLC compared with
patients undergoing conventional 4PLC. Cosmesis is a significant
factor especially in younger patients and those with benign con-
ditions undergoing surgical procedures.24 As such, Dunker et al12
used scaled questionnaires with a single composite score to assess
open versus laparoscopic ileocolic resection for Crohn disease with
regard to differences in cosmetic satisfaction and body image
perception. These are considered patient reported outcomes assess-
ing the patients’ perception of their body and their attitude towards
their appearance and the degree of patient satisfaction with respect to
the appearance of their scars.12 Cosmesis and body image as a
primary endpoint was considered in only 1 SPLC trial, although
follow-up time (1 month) to properly assess cosmesis and body
image was too short to draw reliable conclusions.9,25 In the present
trial, cosmesis and body image were higher in the SPLC cohort
compared with the 4PLC-group 12 weeks and 1 year after surgery,
typically when a surgical scar is expected to have healed completely.
This is of particular interest as the cosmetic benefit for the patient is
the main attraction of SPLC.
Several factors affect intrinsic and extrinsic postoperative
pain, such as incision, bile leakage, intraperitoneal pressure, use
of local anesthetics, peritoneal lavage, and psychological factors.
However, it is well known that the length of incision is the most
important determinant for sensation of pain.9,26–28 Even though there
is some evidence that postoperative pain may be less in patients
undergoing SPLC compared with 4PLC,9,25,29 none of these trials
was blinded with regard to the incisions for patients, treating
physicians, and nurses as suggested in a critical letter from the
Heidelberg group.30 In the present double-blinded trial, postoperative
pain, assessed by the VAS, was significantly lower in the SPLC-
group reflecting less use of paracetamol and metamizole compared
with patients undergoing conventional 4PLC. This positive effect of
TABLE 1. Patient and Operative Characteristics
Characteristics All Patients (n¼ 96) 4PLC (n¼ 48) SPLC (n¼ 48) OR (95% CI) P
Patient
Age (y), mean (SD) 46 (14) 44 (13) 48 (16) – 0.221
Sex, female/male, n 34/62 29/19 33/15 0.69 (0.30–1.61) 0.522
BMI (kg/m2) mean (SD) 25 (4) 26 (5) 25 (3) – 0.109
ASA grade I-II/III, n 68/37/1 31/17/0 37/10/1 – 0.188
Disease, yes/no, n
Cholecystolithiasis 57 26 31 – 0.284
Acute cholecystitis 29 17 12 – –
Gallstone pancreatitis 2 0 2 – –
Other 8 5 3 – –
Comorbidities, yes, n
Cardiovascular 12 6 6 1.00 (0.30–3.35) 1.000
Respiratory 3 1 2 0.49 (0.04–5.58) 1.000
Neurological 6 3 3 1.00 (0.19–5.22) 1.000
Endocrine 9 4 5 0.78 (0.20–3.11) 1.000
Other 14 6 8 0.71 (0.23–2.24) 0.733
Previous abdominal surgery, n operative 31 16 15 1.10 (0.47–2.59) 1.000
Operation duration (minutes), mean, (SD) 95 (39) 90 (41) 101 (36) – 0.031
Cystic artery identified, yes/no, n 88/8 43/5 45/3 0.57 (0.13–2.55) 0.714
Gallbladder perforation, yes/no, n 15/81 8/40 7/41 1.17 (0.39–3.53) 1.000
Cholangiography,y yes/no, n 3/93 1/47 2/46 0.49 (0.04–5.59) 1.000
Conversion,z yes/no, n 2/94 1/47 1/47 1.00 (0.06–16.46) 1.000
Additional trocar, yes/no, n 4/92 0/48 4/44 – 0.117
Intraoperative complication, yes/no, n 3/93 3/45 0/48 – 0.242
Bleeding,§ yes, n 2 2/46 0/48 – 0.495
Bile duct injury, yes, n 0 0/48 0/48 – –
Surgeon comfort with operation yes/no, n 83/13 47/1 36/12 15.67 (1.95–126.12) 0.002
Pearson x2, refers to all disease types.
yIntraoperative cholangiography performed.
z4PLC or SPLC to open cholecystectomy.
§Intraoperative bleeding limited with coagulation and/or clips without requiring any blood transfusion.
Surgeon’s subjective assessment of comfort with operation.
ASA indicates American Society of Anesthesiologists; BMI, body mass index; CI, confidence interval; OR, odds ratio.
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SPLC on pain, noted in the early postoperative phase, might explain
the shorter leave of absence from work in the present collectives,
whereas 12 weeks and 1 year after the procedure no differences were
noted with regard to pain sensation.
Quality of Life has become an important outcome criteria in
single-incision laparoscopic surgery and the disease and its treatment
may have an impact not only on clinical outcome, but also on the
well-being of the individual.31 Although there are currently over 800
different instruments that measure health-related QoL, the most
accepted and validated health profile is the short-form 36 (SF-
36).19 Ma et al evaluated QoL earlier but were unable to detect
any difference between the SPLC and 4PLC- group.32 As stated by
the authors, their trial was not designed to evaluate the differences in
long-term QoL between SPLC and 4PLC, which would be an
interesting point to address in future studies. The present trial is
the first study assessing long-term QoL with the validated SF-36,
showing the positive impact of SPLC 1 year after surgery for both
mental and physical health. This difference was mainly attributed to
the superior emotional well-being and physical pain favoring the
SPLC-group. We interpret this difference based on the personal body
image and sense of attractiveness offered by SPLC coupled by less
scarring and improved cosmesis.
The operating time was 11 minutes longer in the SPLC-group
compared with the 4PLC-group reflecting a technically more
demanding procedure with a certain learning curve. SPLC, however,
proved to be safe as no differences in surgical complications were
noted between both arms. Nevertheless, in 25% of the SPLC cases
(12 out of 48 operations) surgeons complained about discomfort,
which was significantly higher than in 4PLC cases (2%, 1 out of 48).
This lack of surgeon’s confidence might be an important reason why
SPLC has not found wide acceptance until now. In the present trial,
there were no differences in surgical complications between the
4PLC and SPLC study arm. A lack of surgeon‘s confidence, how-
eve,r as noted in SPLC may still influence the rate of complications,
especially the most dangerous and rare ones, such as bile duct
injuries. Even though a recent meta-analysis of 11 RCTs33 did not
show any significant difference in overall biliary complications and
bile duct injuries in patients undergoing SPLC, further well-designed
high volume trials are needed to make final conclusions. Another
reason preventing the implementation of single port technique in
many institutions could be cost related. In addition to the prolonged
operating time, single-use materials, such as the single port system,
the curved single port grasper, and the endocavity retractor, are
required and thus increase economic consumption. Potential com-
pensatory economic effects of a faster time return to work of SPLC
remain questionable.
Some limitations to this trial need to be declared. Firstly,
within the 3-year time frame of the study, a series of patients in
TABLE 2. Cosmesis, Body Image, Pain Assessed by the Visual Analogue Scale, Analgesic Use, and Work Leave
Parameters All Patients (n¼ 96) 4PLC (n¼ 48) SPLC (n¼ 48) P
Preoperative
Body image score, median (IQR) 1 (1–1) 1 (1–1) 1 (1–1) 0.607
Pain VAS, mean (SD) 2.0 (2.2) 1.9 (2.3) 2.1 (2.1) 0.527
Analgesic use,y n yes/no 12/86 3/45 9/39 0.120
Nausea/bloating score, median (IQR) 2 (1–3) 3 (1–3.5) 2 (1–3) 0.154
Operation day
Pain VAS 3.4 (1.8) 4.0 (2.0) 3.0 (1.0) 0.347
Paracetamol, g/d, mean (SD)§ 3.1 (1.4) 3.4 (1.3) 2.9 (1.4) 0.043
Metamizole, g/day, mean (SD)z 2.5 (1.7) 2.7 (1.6) 2.3 (1.8) 0.289
Postoperative day 1
Pain VAS 2.8 (1.8) 3.0 (2.0) 2.6 (2.0) 0.130
Paracetamol, g/d, mean (SD) 2.6 (1.7) 3.2 (1.4) 2.0 (1.8) 0.002
Metamizole, g/d, mean (SD) 2.2 (1.8) 2.7 (1.7) 1.7 (1.8) 0.020
Postoperative day 2
Pain VAS 1.7 (1.5) 2.0 (2.0) 1.0 (1.0) 0.001
Paracetamol, g/d, mean (SD) 2.6 (1.7) 2.8 (1.8) 1.4 (1.7) 0.009
Metamizole, g/d, mean (SD) 2.2 (1.8) 2.5 (1.7) 1 (1.6) 0.005
Postoperative day 7 (outpatient)
Pain VAS 1.9 (1.6) 2.0 (2.0) 1.0 (1.0) 0.005
Nausea/bloating score, median (IQR) 1 (1–2) 1 (1–2) 1 (1–2) 0.444
12 weeks postoperative
Cosmesis score, median (IQR) 19 (14–21) 16 (13–19) 21 (19–23) <0.001
Body image score, median (IQR) 5 (5–6) 6 (5–7) 5 (5–5) 0.013
Pain VAS 0.8 (0.2) 0.9 (0.2) 0.8 (0.2) 0.558
Nausea/bloating 1 (1–2) 1 (1–2) 1 (1–2) 0.859
1-year postoperative
Cosmesis score, median (IQR) 21 (15–24) 16 (13–20) 24 (22–24) <0.001
Body image score, median (IQR) 5 (5–5) 6 (5–7) 5 (5–5) 0.017
Pain VAS 0.9 (0.2) 0.9 (0.2) 0.9 (0.2) 0.067
Nausea/bloating score, median (IQR) 1 (1–2) 1 (1–2) 1 (1–1) 0.010
Work leave, mean total days (SD) 10 (5) 11 (5) 9 (4) 0.050
Umbilical hernia 2 0 2 0.495
Cosmesis score (between 3 and 24, with a high score meaning better cosmetic results). Body image score (between 5 and 20, with a low score meaning a better body image).
Operation day indicates immediately postoperative at the ward.
yRefers to any type of analgesics.
zMetamizole manufactured under the common brand Novalgin (Sanofi-Aventis SA, Vernier, Switzerland).
§Paracetamol manufactured under the common brand Dafalgan (Bristol-Myers Squibb SA, Cham, Switzerland).
CI indicates confidence interval; IQR, interquartile range; VAS, visual analogue scale (0 is no pain, whereas 10 is excruciating pain).
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TABLE 3. Postoperative Complications and Hospital Stay
Characteristics All Patients (n¼ 96) 4PLC (n¼ 48) SPLC (n¼ 48) OR (95% CI) P
Any complication, yes/no, n 23/73 13 10 1.3 (0.52–3.3) 0.642
Clavien-Dindo Complication Grade, n
No complications 73 35 38 – 0.379
Grade I 16 10 6 – –
Grade II 1 0 1 – –
Grade IIIa 4 1 3 – –
CCI of the highest complication, mean (SD) 2.8 (6.3) 2.5 (5.1) 3.2 (7.3) – 0.855
Complication type,y
Self-limited bleedingz 3 2 1 2.1 (0.2–23.8) 0.617
Nausea 14 9 5 2.3 (0.6–6.6) 0.261
Wound infection 3 1 2 0.5 (0.4–5.7) 1.000
Retained bile duct stones 3 1 2 0.5 (0.4–5.7) 1.000
Pneumothorax 1 0 1 – 0.390
Urinary retention 1 0 1 – 0.390
ERCP postoperative 2 1 2 – 0.495
Chest drainage under LA 1 0 1 – 1.000
Hospital stay in days, median (IQR) 2 (2–3) 2 (2–3) 2 (2–3) – 0.720
According to the Clavien-Dindo complication score.
yNo injuries to bowel, bile duct, and other hilar vascular structures.
zPostoperative self-limited bleeding without any blood transfusion administered.
ERCP indicates endoscopic retrograde cholangiopancreatography; IQR, interquartile range; OR, odds ratio; LA, local anesthesia; VAS, visual analogue scale (0 is no pain, whereas
10 is excruciating pain).
TABLE 4. Quality of Life as Assessed by SF-36
Parameters, mean % (SD) All Patients (n¼ 96) 4PLC (n¼ 48) SPLC (n¼ 48) P
Preoperative
Physical activity 87 (19) 87 (20) 86 (20) 0.375
Role limitations due to physical health 79 (36) 74 (39) 81 (33) 0.954
Role limitations due to emotional problems 82 (32) 81 (34) 81 (32) 0.818
Energy/fatigue 62 (20) 62 (21) 60 (19) 0.554
Emotional well being 74 (16) 73 (17) 75 (15) 0.640
Social functioning 83 (23) 80 (24) 85 (22) 0.378
Pain 65 (29) 61 (31) 65 (28) 0.982
General health 69 (18) 69 (18) 67 (17) 0.828
Physical health 83 (18) 83 (19) 83 (17) 0.722
Mental health 80 (18) 81 (19) 79 (17) 0.889
12 weeks postoperative
Physical activity 92 (18) 91 (21) 91 (16) 0.800
Role limitations due to physical health 91 (25) 90 (27) 91 (26) 0.742
Role limitations due to emotional problems 87 (30) 87 (32) 88 (29) 0.873
Energy/fatigue 68 (20) 67 (20) 67 (20) 0.695
Emotional well being 78 (17) 77 (17) 79 (18) 0.461
Social functioning 90 (18) 89 (20) 92 (15) 0.319
Pain 86 (22) 87 (20) 84 (25) 0.558
General health 75 (20) 74 (29) 74 (22) 0.657
Physical health 86 (17) 86 (17) 86 (18) 0.343
Mental health 81 (17) 80 (19) 82 (16) 0.375
1 year postoperative
Physical activity 93 (19) 90 (24) 95 (13) 0.196
Role limitations due to physical health 91 (26) 90 (27) 92 (26) 0.373
Role limitations due to emotional problems 92 (26) 87 (33) 96 (16) 0.152
Energy/fatigue 70 (20) 66 (20) 74 (19) 0.051
Emotional well being 81 (15) 77 (16) 85 (13) 0.015
Social functioning 91 (18) 87 (23) 94 (13) 0.223
Pain 91 (18) 90 (18) 92 (19) 0.047
General health 77 (19) 74 (18) 81 (19) 0.046
Physical health 88 (15) 86 (16) 90 (14) 0.034
Mental health 83 (17) 79 (20) 87 (11) 0.032
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both participating hospitals were not assessed for eligibility. This
was caused not only by the limited availability of surgeons perform-
ing SPLC for the study, but also because of relatively low recruiting
rates for the study. This effect is well known in surgical studies and
has been described previously in detail.34,35 A second limitation
represents the integration of several surgeons from 2 different
centers performing the operations. It is known that individual
surgical attributes lead to variability in practice and health out-
comes. However, the involvement of multiple surgeons, represent
daily practice in gallbladder surgery, which was a target in the
present clinical trial.
To conclude, while there were no differences in surgical
complications and length of hospital stay, the advantages of SPLC
mainly relate to improved short- and long-term cosmesis, body
image, and QoL with a favorable postoperative pain profile and
quicker return to work compared with patients undergoing 4PLC.
Although cost-effectiveness is still a subject of ongoing debate that
needs to be assessed in future clinical trials, SPLC should be offered
to patients undergoing surgery for benign gallbladder disease.
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DISCUSSANTS
M. Krawczyk (Warsaw, Poland):
First of all I would like to thank ESA for giving me the
privilege to be the first discussant on this excellent study. I would like
to congratulate the authors on preparing the study on a very topical
subject concerningLC. Although my first reaction when I had read
the manuscript was that even the surgeons with little experience in
surgery know, without referring to any study, that 1 incision causes
less pain than 4 incisions and that 1 incision from the cosmesis point
of view is better than 4. I must admit that the strong side of the study
is the methodology. Congratulations!
Allow me now to present my questions. Firstly, why have you
decided that endpoint in cosmesis is a 20% improvement, especially
that you used the body image questionnaire, which ranges from 8 to
44 points? My second question concerns the incisional hernia. You
found 2 umbilical hernias in a single-port operation. I presume that in
reality it is more important than a positive effect on cosmesis in the
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remaining patients in the group. Could you comment on this prob-
lem? The third question concerns the training of the surgeon. The 4
trocars LC is a common operation mastered by most surgeons,
whereas single trocar is a much more difficult procedure. You did
not mention that it is necessary to have extra training and that it
makes the operation more expensive.
Response From G. Lurje (Aachen, Germany):
Thank you, professor Krawczyk, for your comments. I will try
to answer them point-by-point. Your first comment addressed power
calculations and cut-off of our primary endpoints for cosmesis and
body image. We estimated our sample size calculation by using
available data at the time of the trial design. In clinical trials, a 20%
improvement in outcome is generally regarded as significant. We
made an arbitrary estimation at the time of the trial design, as no
other studies were available evaluating cosmesis and body image in
SPLC. With regards to your second question, incisional hernias are
obviously a frustrating issue, especially in single-port surgery. We
had 2 hernias in our study cohort. One of these patients was
unknowingly pregnant during the time of the operation, and she
developed an incisional hernia during pregnancy. Nevertheless, this
study was not designed to address this topic appropriately, and this
may require further analyses.
In response to your final comment, cost-effectiveness in health-
care and medical training has always been key concerns. SPLC is
clearly a more demanding surgical procedure compared with the
conventional 4-port cholecystectomy. Costs are generally believed
to be higher in SPLC due to the comparatively expensive instruments
needed for the procedure. Nonetheless, reliable predictions regarding
costs cannot bemade at this stage as cost-effectiveness is influenced by
various factors, such as return towork after surgery.We are planning to
perform a comprehensive cost effectiveness analysis for the future.
N. Senninger (Mu¨nster, Germany):
I enjoyed your presentation. However, I have some remarks.
First of all, at the German Surgical Congress just 10 days ago, we
discussed the same matter; and the opinion was that single-port is not
superior, if at all equal in a selected group of patients. Secondly, if
there were complications, they were usually more severe. The inci-
sional hernia and the secondary healings around an umbilicus were
much more severe in single-port surgery than after conventional
laparoscopic operations. You gave us the grade 3A complications
according to Clavien-Dindo. There were 3 in the single-port versus
none in the conventional laparoscopic group, which is relevant
although in your study not significant because the numbers are
too small. I do not believe that you really can double-blind a study
like this. Even if you put dressings on the abdominal wound on 4
places the patient will realize that there is no incision underneath.
This makes me ask whether the patients were influenced towards a
positive opinion in the SILS-group.
Response From G. Lurje (Aachen, Germany):
Thank you Professor Senninger for your comments. With
regards to your first remark, I am not sure what kind of studies
were discussed at the German Surgical Meeting. Nevertheless, a
recent meta-analysis of 7 randomized controlled trials (RCT) com-
prising 855 patients by the Cochrane Hepato-biliary Group did not
show significant differences in surgical complications between SPLC
and conventional 4-port cholecystectomy. Despite the fact that
surgical complications were not the primary endpoint of our study,
we did not observe any statistical differences either. The primary
endpoint of this present study was cosmesis and body image. Our
trial is not powered to draw final conclusions on incisional hernias,
even though we did not observe any significant differences in
our cohort.
In response to your comments on the legitimacy of double-
blinding, I agree with you that this is a difficult task. Double-blinding
was essentially used for the assessment of postoperative pain, and we
did not detect that the patients could be aware of the group they
belong to. Thus, we believe that patients were not influenced towards
a positive opinion for one or the other study-arm.
W.A. Bemelman (Amsterdam, The Netherlands):
I am glad to see that you still use the body image and
cosmesis questionnaires that we developed almost more than 20
years ago. We have had difficulties finding differences in body
image in patients with inflammatory bowel disease (IBD) compar-
ing midline laparotomy with Pfannenstiel incisions or midline
laparotomy with port sites. So why is your effect you found so
big? It is a relatively significant effect for let us say a small
difference in scars.
Response From G. Lurje (Aachen, Germany):
Thank you Professor Bemelman for your comments.We found
your cosmesis questionnaires to be quite appropriate for this type of
study design. In this age of scarless and minimal invasive surgery, the
patient’s expectations from surgical procedures have increased. We
therefore assume that the significance of the relatively small differ-
ence in scarring has also increased.
W.A. Bemelman (Amsterdam, The Netherlands):
I have a short second question. Was there a difference between
men and women? Men, like women, care about cosmesis, but unlike
women they are less affected considering body image.
Response From G. Lurje (Aachen, Germany):
Thank you very much for raising this interesting point about
possible sex differences, but we did not observe any sex-related
discrepancies, although the study was not designed to answer this
question.
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